Tag: the war on (some) drugs

Controversies Involving Speaker Mike Johnson and His Son Resurface — From Monitoring Each Other’s Porn Usage to Arrest of His Adopted Son on Charges of Running Illegal Cannabis Business

Speaker Mike Johnson finds himself entangled in controversy once more, as past incidents involving his ‘adopted’ son resurface amidst legislative tumult.

Last week, the House of Representatives, under Johnson’s leadership and his comrades, passed two “America last” legislations.

Firstly, the House approved an extension of Section 702 of the Foreign Intelligence Surveillance Act (FISA), a measure initially enacted following the September 11, 2001, attacks, in a 273 to 147 vote. This provision allows for the warrantless surveillance of American citizens, a move that has raised concerns about privacy and civil liberties.

An amendment proposed by Rep. Andy Biggs, which sought to impose a requirement for the FBI to obtain a warrant before conducting surveillance on Americans under FISA, ended in a 212-212 tie vote, leading to Speaker Mike Johnson casting the tie-breaking vote against the amendment.

This decision drew sharp criticism, including conservative commentator Charlie Kirk, who accused Johnson of betraying the American people and undermining the Constitution.

In an attempt to halt the momentum of the FISA Section 702 extension, Rep. Anna Paulina Luna employed a procedural strategy to delay the Senate’s consideration of the bill. Despite her efforts, the bill passed again. The vote displayed a uniparty alliance, with 147 Democrats and 126 Republicans supporting the bill, while 88 Republicans and 59 Democrats opposed it.

The second major legislative action under Speaker Johnson involved the passing of three bills aimed at providing financial aid to Ukraine, Israel, Gaza, and other regions engaged in conflicts outside U.S. borders.

The Democrats waved Ukrainian flags on the floor of the United States House of Representatives as they voted to send $60 BILLION of taxpayer money to secure a foreign border.

Keep reading

Senator Tom Cotton Demands Secret Service Release ALL Info Related to Cocaine Found in White House

Senator Tom Cotton of Arkansas is demanding that the Secret Service turn over all information regarding the cocaine recently discovered in the White House.

The story about where the drugs were found keeps changing and Tom Cotton rightly calls this a national security issue. If someone can sneak illegal drugs into the White House, what is to stop someone from sneaking a much more dangerous substance into the building?

The media is preparing to drop the story and move on because they want to protect Biden. Cotton is not letting it go away.

The Daily Mail reports:

Top Republican Senator demands Secret Service release ALL information on White House cocaine – including lists of guests who avoided screenings – to determine if President’s home is secure

Sen. Tom Cotton wants more clarity after the Secret Service found cocaine inside the White House over the weekend – and is demanding Americans and Congress receive their well-deserved answers.

Cotton, the top Republican on the Criminal Justice and Counterterrorism Subcommittee, wrote a letter to U.S. Secret Service (USSS) Director Kimberly Cheatle on Wednesday with six questions he wants answered.

He demanded that Cheatle schedule a briefing with his staff.

‘Congress and the American people deserve to know how cocaine got into the White House,’ he said in a tweet along with an image of the letter…

‘According to public reports, the Secret Service has not yet confirmed where in the West Wing the cocaine was found,’ Cotton wrote in his Wednesday letter. ‘I urge you to release that information quickly, as the American people deserve to know whether illicit drugs were found in an area where confidential information is exchanged.’

Keep reading

Recreational cannabis use may lower your risk of cognitive decline, study says

When you light up or down an edible, you may be lowering your risk of cognitive decline, according to a new study comparing recreational cannabis users to nonusers. As marijuana isn’t without its health harms, these findings came as a surprise even to the scientists behind the study.

Researchers at the State University of New York Upstate Medical University found that nonmedical cannabis use—regardless of how or how often it was consumed—lowered a person’s odds of subjective cognitive decline (SCD) by 96%. The results were published in February in the journal Current Alzheimer Research. 

“I was expecting cannabis to be linked to an increased risk for cognitive decline, because that’s pretty much what’s consistent in previous research,” study coauthor Roger Wong, Ph.D., an assistant professor of public health and preventive medicine at the university’s Norton College of Medicine, tells Fortune. “I was stunned by the opposite finding.”

Dual use of cannabis, for both medical and nonmedical purposes, as well as medical use alone also correlated to decreased risk of SCD, the self-reported worsening or increased frequency of confusion or memory loss. However, those associations weren’t statistically significant.

Previous research suggests people with SCD are 2.5 times more likely to develop dementia and 1.8 times more likely to develop mild cognitive impairment. About one in nine U.S. adults ages 45 and older experience SCD, according to the Centers for Disease Control and Prevention (CDC).

“We don’t have a way to prevent dementia right now,” Wong says. “But if we can prevent subjective cognitive decline at the very beginning and track it, that’ll hopefully fix some of the issues that we’re having right now with dementia later in life.”

Keep reading

Personalised medicine will make drug experimentation on populations the norm

In June 2023, the UK’s Medicines and Healthcare products Regulatory Agency (“MHRA”) announced it will be the first drug safety regulator in the world to pilot its own genetic “biobank,” to better understand how a patient’s genetic makeup can impact the safety of their medicines.

“The Yellow Card biobank, which will contain genetic data and patient samples … forms part of a long-term vision for more personalised medicine approaches … [to] enable doctors to target prescriptions using rapid screening tests, so patients … receive the safest medication for them, based on their genetic makeup,” a press release said.

In February 2024, as a personalised medicine project, the MHRA began recruiting patients who have experienced excessive bleeding after taking blood thinners to establish whether they have any special genetic traits which predispose them to excessive bleeding.

It may sound exciting however, personalised genetic medicine is a step towards an era where drug use and experimentation on populations become the norm.

As Dr. Guy Hatchard notes, whilst most pharmaceutical drugs entail adverse reactions and unanticipated side effects, drugs that are tailored to genetic characteristics may potentially have even more serious consequences and long-term adverse outcomes. This is because genetic systems are involved in all the functions of the physiology, its organs, bio-molecular messaging and overall immunity.

Keep reading

Pennsylvania GOP Senator’s Bill Would Let Medical Marijuana Patients Get Gun Carry Permits

A Republican senator in Pennsylvania has formally introduced a bill meant to remove state barriers to medical marijuana patients carrying firearms after previewing the legislation and soliciting co-sponsors earlier this year.

Sen. Dan Laughlin (R) introduced SB 1146 on Wednesday, which state Senate Republicans noted in a press release was also 2A Day, celebrating the Constitution’s Second Amendment.

The GOP statement called the proposal “a bold step toward ensuring the rights of all citizens,” saying it “acknowledges the importance of the right to bear arms, a fundamental aspect of American freedom.”

“My legislation will make sure a valid medical marijuana cardholder is no longer considered an unlawful marijuana user,” Laughlin said in the release. “Although marijuana remains illegal under federal law, we should be updating Pennsylvania’s laws to ensure valid medical marijuana cardholders are not denied their rights.”

The two-page bill would amend the Pennsylvania’s Uniform Firearms Act, which currently says a concealed carry license “shall not be issued” to someone who “is addicted to or is an unlawful user of marijuana.” SB 1146 would add that “the term ‘unlawful user of marijuana’ does not include an individual who holds a valid identification card” under the state’s medical marijuana act.

It would also add a qualifier to a provision barring carry permits for an “individual who is prohibited from possessing or acquiring a firearm under the statutes of the United States,” asserting that the restriction “shall not apply” to someone prohibited from gun ownership “based solely on the individual’s status as a holder of a valid identification card” for medical marijuana.

The changes would take effect 60 days after becoming law.

Keep reading

Colorado Senate Passes Bill That Could Ban Social Media Users Who Post Positively About Drugs—Including Legal Psychedelics

Colorado’s Senate has approved a sweeping social media bill that, among other provisions, could force platforms to ban users for talking positively online about certain controlled substances, such as state-legal psychedelics, certain hemp products and even some over-the-counter cough syrups.

The legislation, SB24-158—a broad proposal concerning internet age verification and content policies—would require social media platforms to immediately remove any user “who promotes, sells, or advertises an illicit substance.”

Initially that provision would have applied to all controlled substances under state law—including state-legal marijuana—but an amendment last month from the bill’s sponsor, Sen. Chris Hansen (D), includes language saying that “a social media platform may allow a user to promote, sell, or advertise medical marijuana or retail marijuana to users who are at least twenty-one years of age” so long as the content complies with state cannabis laws.

The amended legislation would still apply to numerous other legal and illegal substances.

On Wednesday, the Senate voted 30–1 to pass the revised measure on third reading, with four members excused.

Earlier this week, the Senate Appropriations Committee also adopted two amendments to the bill, including one adding staff funding for the state attorney general’s office and another that could make the act subject to voter approval in November.

Critics say even with the marijuana-related amendment, the bill could create major problems for users trying to post benign—and legal—content around substances like cough medicine.

Keep reading

DeSantis Again Rips Into Marijuana Legalization, Warning November Ballot Measure Would Be ‘Not Good For Families’

With a legalization ballot measure set to appear on Florida’s ballot in November, Gov. Ron DeSantis (R) again attacked the proposal on Wednesday, warning that the changes would be “not good for families” and “not good for [the] elderly.”

He also accused the initiative’s cannabis industry backers as being profit-driven. “People aren’t putting tens of millions of dollars behind that out of the goodness of their heart,” the governor said. “They are going to be making a lot of money if that amendment passes, so you’d be making some companies very, very rich.”

DeSantis has previously predicted voters will reject the marijuana initiative in November and argued that passage would “reduce the quality of life” in the state.

Speaking at an event on Wednesday, DeSantis urged voters to reject ballot initiatives that might seem vague or confusing—including the cannabis measure.

“The marijuana one is written so broadly, you are not going to be able to restrict where people use it,” DeSantis said, repeating a claim that the legalization campaign has said is untrue. “Understand: Your life will be impacted by this. It will change the quality of life and our communities. You will smell it when you’re walking down a lot of these streets, particularly in our urban areas.”

Keep reading

Researchers Ask Federal Court To Block DEA From Banning Two Psychedelics Under ‘Unconstitutional’ Administrative Process

Researchers are asking a federal court to block the Drug Enforcement Administration (DEA) from proceeding in its attempt to ban two psychedelics, arguing that the agency’s administrative approach to the proposed scheduling is unconstitutional.

Panacea Plant Sciences (PPS) filed a complaint and request for injunctive relief against DEA in the U.S. District Court for the Western District of Washington last week.

The legal challenge focuses on the agency’s recent scheduling of an administrative hearing to receive expert input on its controversial plans to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA).

The filing doesn’t speak to the merits of the scheduling proposal—an issue that psychedelics researchers have previously addressed in public comment. Rather, PPS is contesting the administrative hearing process that’s preceding final rulemaking, arguing that DEA’s reliance on administrative law judges (ALJs) to settle such arbitration is unconstitutional based on U.S. Supreme Court precedent.

PPS said that because the Supreme Court has held that ALJs are considered “inferior officers,” current statutory removal protections unconstitutionally insulate them from executive control under Article II of the Constitution. That means DEA should not be permitted to subject researchers to an administrative hearing concerning the psychedelic scheduling proposal, the filing says.

“The hearing and scheduling poses a significant threat to the company,” it says. “PPS conducts research and development on medical technologies which include the use of DOI or DOC for development and as products themselves. Currently, DOI and DOC are not controlled.”

“Under the Controlled Substances Act (CSA) and its implementing regulations, PPS will be required to turn over to law enforcement or destroy our stock of DOI and DOC which means the rule-making acts as an effective taking of property,” the document says.

“As a result, when PPS received the hearing notice from DEA, it was faced with a stark choice: either default and lose automatically or defend itself against the DEA’s attempts to schedule DOI and DOC and its use of an ALJ-overseen adjudication,” it continues. “PPS is thus compelled to participate in the DEA’s adjudicatory proceedings.”

Keep reading

Fentanyl Fear Factor: White House Leverages Drug Scare to Push for Controversial Surveillance Powers

In a recent public appeal, the Biden administration has urged the reauthorization Section 702 of the Foreign Intelligence Surveillance Act (FISA) before it expires on April 19. Bill Burns, the CIA Director, issued a statement, alleging the significant role of the FISA powers in fighting threats against national security, especially the illicit trafficking of fentanyl into the United States.

Burns highlighted the gravity of the fentanyl threat, saying, “The threat to the US posed by fentanyl and other synthetic opioids is real. Section 702 is an essential tool in CIA’s mission to protect the American people from a range of threats, including illicit fentanyl trafficking. Without this vital program, CIA simply would not be able to defend our country as effectively in as many dangerous corners of the world.”

Echoing the CIA Director’s stance, the White House has also underlined the importance of the reauthorization bill in ensuring national security. National Security Communications Advisor John Kirby further stressed the significance of bipartisan support for this endeavor. He stated, “Obviously we strongly support the bipartisan effort to get 702 reauthorized. It is vital to our ability to defend ourselves, defend … the American people, and we very much want to see it move forward — get extended and move forward.”

It’s worth noting that Section 702 of FISA authorizes US government officials to collect electronic communications without needing a warrant. This provision has been a point of contention, with privacy advocates arguing that it infringes on personal freedom.

Keep reading

After Virginia GOP Governor’s Marijuana Veto, Democratic Senators Say Legal Sales Likely Won’t Happen Until 2027 Or Later

Democratic senators in support of legal marijuana sales in Virginia said at a recent event that in light of Gov. Glenn Youngkin’s (R) veto of a retail cannabis bill last month, it will likely be 2027 or later before adult-use shops can legally open their doors.

“I’m very direct, and sometimes folks don’t like to hear the harsh truth, but it’s the harsh truth,” said Sen. Aaron Rouse (D), who sponsored the retail sales bill in the Senate. “There’s a really big mountain to climb with this governor and his administration. I think he will veto setting up an adult cannabis market regardless of what we send him.”

“By 2027, there will be a new governor in Virginia,” added Sen. Adam Ebbin (D), who sponsored marijuana sales legislation this session and in years past. “It’s possible that after the 2025 gubernatorial election, that someone will take office in January of 2026 who would sign an adult-use marketplace bill.”

“That means that, whether it was in 2027 or thereabouts,” Ebbin continued, “we could expect to see more a regulated market for non-medical use or adult use in Virginia.”

Use, possession and limited cultivation of cannabis by adults is already legal in the commonwealth, the result of a Democrat-led proposal sponsored by Ebbin that was approved by lawmakers in 2021. But Republicans, after winning control of the House and governor’s office later that year, subsequently blocked the required reenactment of a regulatory framework for retail sales.

This year, with Democrats in control of both legislative chambers, lawmakers passed a new legal sales bill, sending it to Youngkin for his consideration in late February. A month later, the governor vetoed the bill, writing in a veto message that “the proposed legalization of retail marijuana in the Commonwealth endangers Virginians’ health and safety.”

Keep reading